A comparison of SARS-CoV-2 antibody profiles in elderly and younger individuals
In a recent Scientific Reports study, researchers comparatively evaluate antibody titers after double vaccination with the Pfizer-BioNTech BNT162b2 messenger ribonucleic acid (mRNA) vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among very elderly individuals over the age of 90 and a younger population between the ages of 23 and 69 years. Previous studies have reported a progressive decrease in responses […]
» Read more